You're paying $299 to $449 a month. Roughly a quarter of what you've lost is muscle — and nobody is measuring it.
Whether you're holding, cycling, or planning to stop, the risk moved downstream: to lean mass you can't see leaving, deficiencies nobody tests for, and regain that starts the week you stop. We sell the measured exit.
Every company with distribution earns money when you stay on the drug. That is not a conspiracy, it's an incentive — and it means nobody in the chain is paid to help you land. The clinics that started you have nowhere to send you. The manufacturers sell refills. The one large player that isn't conflicted can't prescribe.
So the exit is unmanaged, and it's the part with the risk in it. We measure what's actually leaving, set the protein and training targets against your own numbers rather than a chart average, step the dose down on a schedule a prescriber executes, and keep measuring quarterly — on the drug or off it.
Most of this category sells plausible as proven. We'd rather show you the grading and lose the sale.
| Claim | Grade |
|---|---|
| GLP-1s produce substantial weight loss | Proven |
| A meaningful share of that loss is lean mass | Proven |
| Adequate protein plus resistance training preserves lean mass in a deficit | Proven |
| A structured, measured taper reduces regain — no published clinical standard for GLP-1 de-prescribing exists anywhere. We're authoring one and saying so. | Plausible |
| “Microdosing” a GLP-1 indefinitely for maintenance | Marketing |
| Compounded peptide stacks and blends for the maintenance phase | Marketing |
Not a sales script and not a nurse line — the person building this. We'll go through where you actually are, what your numbers are likely doing, and whether this is worth your money. If it isn't, we'll say so.
No card, no deposit, nothing to cancel. If you'd rather not talk to anyone yet, switch to the second tab and we'll send the plan instead.